FDA Approves First Ready-to-Use Liquid Stable Glucagon Gvoke

9/10/19
WRITTEN BY: Beyond Type 1 Editorial Team
FacebookTwitterEmail
 

On September 10, the FDA approved the Gvoke HypoPen, an emergency glucagon rescue treatment for severe hypoglycemia. The device from Xeris Pharmaceuticals contains a room temperature, liquid-stable form of glucagon that is auto-injected when pressed against the body, similar to how an EpiPen works to treat severe allergic reactions. Gvoke is formulated for use in patients over the age of two and can be administered by caregivers in emergency situations of hypoglycemia.

Once administered, the glucagon works to rapidly increase blood glucose levels by stimulating the liver to release accumulated glucose into the bloodstream. Also approved was the Gvoke PFS, a pre-filled syringe with the same liquid-stable form of liquid glucagon found in the HypoPen. Both options will be available in two doses: a 0.5 mg/0.1 mL dose for pediatric patients and a 1 mg/0.2 mL dose for adolescents and adults.

“This milestone is a positive step forward for the diabetes community as the first pre-mixed, pre-filled, and pre-measured liquid glucagon to effectively treat severe hypoglycemia in both adults and children with diabetes,” said Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals. “We are actively preparing to introduce Gvoke in two different administration options to accommodate the community’s preferences starting with our pre-filled syringe in 4-6 weeks and the auto-injector in 2020.”

For decades, a Glucagon emergency kit had been the only FDA-approved way to administer glucagon in cases of severe hypoglycemia. However, injectable glucagon was not previously not liquid-stable at room temperature and therefore required mixing a powder and liquid with a syringe, which can be intimidating and prone to user error in emergency situations.

“Until now, many people may have been hesitant to use conventional glucagon kits because the complex preparation felt confusing and perhaps overwhelming. With Gvoke as a new glucagon option, we gain an easy to use and effective solution to a dangerous and stressful event,” said Jeff Hitchcock, founder and president of Children with Diabetes.

FDA approval came after positive results from Phase 3 clinical trials comparing the use of Gvoke to conventional glucagon rescue kits in situations of severe hypoglycemia in both children and adults. These trials saw a 100% treatment success rate in children, and a 99% success rate in adults.

These new, liquid-stable glucagon kits from Xeris represent the second approval of next-generation glucagon in the past two months. In July, the FDA approved the first non-injectable form of glucagon, BAQSIMI. The rescue device from Eli Lilly is a powder form of glucagon administered into the nose, and comes in a single-use dispenser.

The list price for Gvoke will be the same as the list price for current Glucagon Emergency Kits and BAQSIMI, $280.

Edick said on a conference call earlier today that Xeris is working to get their product onto insurance formularies and additionally will be launching a co-pay assistance program for people with commercial insurance, as well as a program in place for people who do not have health insurance. He concluded with “We want to make it as easy, and simple, and inexpensive as possible for patients to gain access to our products”

Although the HypoPen and PFS are currently only approved to treat severe hypoglycemia, a liquid-stable form of glucagon opens the door to approval for a wider range of future use cases for the drug. Edick told Beyond Type 1 earlier this year that the company was looking at the potential for their product to treat both exercise-induced hypoglycemia and post-bariatric surgery hypoglycemia.

For more information on Gvoke visit www.gvokeglucagon.com.



Beyond Type 1 Editorial Team

This piece was authored collaboratively by the Beyond Type 1 Editorial Team. Members of that team include Editorial Manager Todd Boudreaux, Program Manager Mariana Gómez, Director of Brand Communications Dana Howe, and Associate Editor Jordan Dakin.